Arcturus Therapeutics

Arcturus Therapeutics is a preclinical drug delivery and RNA medicines company. We are focused on developing novel technologies to build the next generation of safe, effective RNA and DNA medicines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics.

Placeholder

Arcturus Therapeutics

  • Synthetic GenomicsArcturus Therapeutics Announces Strategic Alliance with Synthetic Genomics, Inc. to develop self-amplifying RNA-based vaccines and therapeuticsREAD MORE
  • Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA MedicinesREAD MORE
  • Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation to Advance a Novel LUNAR-Formulated mRNA CFTR TherapeuticREAD MORE
  • Takeda Pharmaceuticals logoTakeda Pharmaceuticals entered into collaboration with Arcturus Therapeutics to develop RNA-based therapeutics for the treatment of NASH.READ MORE
  • Ultragenyx Pharmaceutical Inc. entered into a research collaboration and license agreement with Arcturus to discover and develop messenger RNA (mRNA) therapeutics.Ultragenyx Pharmaceutical Inc. entered into a research collaboration and license agreement with Arcturus to discover and develop messenger RNA (mRNA) therapeutics.READ MORE

LUNAR®-mediated delivery of RNA into cells

LUNAR particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR® lipid mediated delivery enables delivery of RNA medicines.

News & Events

  • March 18, 2019

    Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results

    • March 18 2019
    • 0
    read more
  • February 11, 2019

    Arcturus Therapeutics to Present at Upcoming Investor Conferences

    • February 11 2019
    • 0
    read more
  • February 11, 2019

    Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency

    • February 11 2019
    • 0
    read more
  • January 3, 2019

    Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer

    • January 3 2019
    • 0
    read more
  • January 2, 2019

    Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

    • January 2 2019
    • 0
    read more
  • December 3, 2018

    Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11

    • December 3 2018
    • 0
    read more
  • November 7, 2018

    Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results

    • November 7 2018
    • 0
    read more
  • November 5, 2018

    Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility

    • November 5 2018
    • 0
    read more
  • October 1, 2018

    Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    • October 1 2018
    • 0
    read more